A critical leap in immunization strategies involves optimizing how antigens reach immune cells, and novel vaccine delivery systems are making this possible. Nanoparticles, microneedles, viral-like particles, and lipid-based carriers are among the innovative platforms reshaping delivery routes. These technologies offer enhanced stability, targeted cellular uptake, and controlled antigen release—minimizing dosage while maximizing immune activation. Intranasal, oral, and transdermal methods are being refined to improve patient compliance and eliminate the need for cold chain logistics. Researchers are also investigating self-amplifying RNA and implantable delivery devices for long-lasting immunity. The convergence of materials science and immunology is creating systems that go beyond injection-based models, with implications for both human and veterinary medicine. As regulatory bodies adapt to these innovations, Novel Vaccine Delivery Systems are poised to redefine the speed, accessibility, and efficacy of global immunization programs.
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States
Title : Hypersensitivity and anti-SARS-COV-2 vaccination: A retrospective study of the year 2021 at the University Hospital Center of Tours (France)
Faure Quentin, The Savoie Metropolitan Hospital Center, France
Title : THE HPV vaccination program in Colombia. From a beautiful dream to a nightmare, but hopefully with a bright dawn.
Carlos Castro, Colombian League against cancer, Colombia